Radboud University Medical Center
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Private
- Established
- 1951-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.radboudumc.nl
Effectiveness of Insignia ™ Versus Standard Orthodontic Treatment With Damon Q Brackets
Not Applicable
Completed
- Conditions
- InsigniaOrthodontic TreatmentFixed AppliancesDamonQ Brackets
- Interventions
- Device: Damon self ligating orthodontic bracketDevice: Insignia self ligating orthodontic bracket
- First Posted Date
- 2010-12-31
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 180
- Registration Number
- NCT01268852
- Locations
- 🇳🇱
Department of Orthodontics and Craniofacial Biology, Nijmegen, Gelderland, Netherlands
Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion
Phase 2
Terminated
- Conditions
- Malignant AscitesMalignant Pleural Effusion
- Interventions
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT01262612
- Locations
- 🇳🇱
University Medical Centre Nijmegen, Nijmegen, Gelderland, Netherlands
Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus
Phase 2
Terminated
- Conditions
- Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus
- Interventions
- Drug: CRT + PanitumumabDrug: Concurrent chemoradiation therapy without panitumumab
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2012-05-11
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 4
- Registration Number
- NCT01262183
- Locations
- 🇳🇱
University Medical Centre Nijmegen, Nijmegen, Gelderland, Netherlands
Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease
Phase 2
Completed
- Conditions
- Leukemia, Myeloid, AcuteLeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT01249820
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
International Validation of a Delirium Prediction Model for ICU Patients
Completed
- Conditions
- Delirium
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 2000
- Registration Number
- NCT01249755
Sugarsquare. Focus on the Adolescent: Digital Treatment of Type 1 Diabetes Through the Internet
Not Applicable
Completed
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2010-11-30
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 65
- Registration Number
- NCT01249742
- Locations
- 🇳🇱
Children's Diabetes Center Nijmegen, Nijmegen, Gelderland, Netherlands
Parkinson's Disease, Diagnostic Observations (PADDO)
- Conditions
- Parkinson's DiseaseAtypical Parkinsonism
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 150
- Registration Number
- NCT01249768
- Locations
- 🇳🇱
Radboud University Medical Centre, Nijmegen, Netherlands
Sunitinib and Atrial Trabeculae Contractility
Completed
- Conditions
- CardiotoxicityIschemiaHeart Failure
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01246778
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
MIBG Scintigraphy and Strain Echocardiography in the Detection of Subclinical Cardiovascular Effects One Year After (Neo)Adjuvant Breast Cancer Treatment With Docetaxel, Doxorubicin and Cyclophosphamide (TAC): a Pilot Study
- Conditions
- Breast Cancer
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2011-09-12
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 150
- Registration Number
- NCT01246856
- Locations
- 🇳🇱
University Medical Centre Nijmegen, Nijmegen, Gelderland, Netherlands
Temsirolimus-RCC-imaging
Phase 2
- Conditions
- Renal Cell Cancer
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 51
- Registration Number
- NCT01246817
- Locations
- 🇳🇱
University Medical Centre Nijmegen, Nijmegen, Gelderland, Netherlands
© Copyright 2025. All Rights Reserved by MedPath